Blood glucose and liver function in dogs administered a xylitol drinking water additive at zero, one and five times dosage rates

Main Article Content

James M.G. Anthony *
Lynn P. Weber
Stan Alkemade
(*) Corresponding Author:
James M.G. Anthony | james.anthony@usask.ca

Abstract

A study was designed to determine the safety of a drinking water additive that reduces plaque and calculus in dogs, and contains xylitol as an active ingredient. The randomized, double-blind, placebo-controlled study was performed in 15 crossbred dogs that were randomly divided into three groups and had their drinking water treated for 14 days with either: i) a commercial health care product (BreathaLyser Plus) at the recommended dosage, ii) an experimental health care product (BreathaLyser Plus containing five times the amount of xylitol), or iii) a placebo of purified water with a colour additive. Results demonstrated that the continuous administration of a commercial, drinking water, oral health product containing xylitol, at one and five times the normal inclusion rate, does not cause hypoglycemia or alter liver function in dogs.

Downloads month by month

Downloads

Download data is not yet available.

Article Details

Author Biographies

James M.G. Anthony, University of Saskatchewan

Dept SACS, WCVM, University of Saskatchewan

Lynn P. Weber, University of Saskatchewan

Veterinary Biomedical Sciences, University of Saskatchewan